Fresh from a $105 million third-round financing earlier this month, ALX Oncology has won two FDA fast-track designations for its lead immuno-oncology drug. The Irish-American biotech picked up the ...

ALX Oncology, a Bay Area biotech firm currently running clinical trials for its anticancer therapy, announced Wednesday that it’s laying off about 30% of its staff. ALX shared the news in a ...

NATL, BGC, NPSNY, ALX and VEEV have been added to the Zacks Rank #1 (Strong Buy) List on April 3, 2025. ALX, AVGO and BNPQY made it to the Zacks Rank #1 (Strong Buy) income stocks list on April 3 ...